Ascendis Pharma A/S

Ascendis Pharma A/S, based in Denmark, is dedicated to developing innovative biopharmaceuticals through its proprietary TransCon™ technology platform, focusing on addressing unmet medical needs in endocrinology, rare diseases, and oncology. Ascendis Pharma A/S specializes in biopharmaceutical development. Founded in 2007 in Denmark, the company has undergone multiple funding rounds, with the most recent being a Series A round in September 2017, raising USD 150. 00 mn led by Frazier Healthcare Partners.

The current CEO is Jan Mikkelsen. Ascendis Pharma specializes in the development of innovative biopharmaceuticals utilizing its proprietary TransCon™ technology platform. The company's core product offerings include therapies designed to address unmet medical needs in the fields of endocrinology, rare diseases, and oncology. Notably, Ascendis Pharma's flagship products, such as TransCon hGH for growth hormone deficiency and TransCon PTH for hypoparathyroidism, are engineered to enhance treatment safety and efficacy while improving patient convenience and tolerability.

These therapies are currently in clinical development phases and are targeted to serve healthcare providers and patients primarily in the United States and Europe, with ongoing partnerships for potential expansion into additional markets. Ascendis Pharma generated revenue of USD 393. 54 mn in 2024. The company recorded an EBITDA of USD -304.

22 mn in the same year. Revenue comes from the commercialization of its TransCon™ products through established partnerships with healthcare providers and pharmaceutical distributors, as well as strategic collaborations with biotech firms and research institutions. Ascendis Pharma aims to utilize the recent funding from its Series A round to support drug manufacturing, advance the development of preclinical drug candidates, and enhance its clinical research and development. The company plans to launch new products targeting unmet needs in the market, particularly in endocrinology and rare diseases.

Additionally, it is focused on expanding its market reach into Europe and other regions by the end of 2025.